Alchemab Unveils ATLX-1088 Antibody

Alchemab Unveils ATLX-1088 Antibody Alchemab Therapeutics, a company that studies antibodies naturally occurring in disease-resistant individuals, announced the disclosure of data regarding newly discovered ATLX-1088, which could be used in Alzheimer's disease prevention. ATLX-1088 is a specially designed antibody targeting CD33, a cell surface protein thought to play an important role in Alzheimer's disease. Studies have shown that higher expression of CD33 is associated with more advanced cognitive decline and worsening disease status; because high CD33 levels interfere with the normal function of microglia, resident immune cells in the brain that protect and repair neural networks. After identifying common antibodies specific to Alzheimer's disease-resistant individuals, Alchemab identified CD33 as the target. Alchemab's platform reverses the traditional "target-focused" drug discovery process, starting from the body's response to disease rather than the target itself. The immune system is used as a search function to identify the most important disease-modifying targets. Another advantage of this approach is that the disease-modifying antibody is naturally optimized by the immune system, which can enable the development of beneficial properties from a therapeutic perspective. Source